Dr Reddy's gets US FDA nod for marketing Ciprofloxacin

Mumbai: Dr Reddy's Laboratories Ltd has received approval from the US Food and Drug Administration to market its anti-infective Ciprofloxacin extended-release tablets.

The drug maker also received approval to market Rivastigmine Tartrate capsules, a generic variant of Novartis' Exelon capsules, indicated in the treatment of mild dementia associated with Alzheimer's disease and Parkinson's disease, USFDA said in statement in its website.